When the HR for TTR events was adjusted for factors known to affect prognosis (age, vascular invasion, oestrogen-receptor status, HER2 status, nodal status, tumour grade, and tumour size) the value for accelerated epirubicin compared with standard epirubicin was 0·95 (95% CI 0·82–1·10; p=0·48). The gene discussed is TTR; the disease is neoplasm.